The GSP Neonatal 17α-OH-progesterone assay is intended for the quantitative determination of 17OHP in dried blood spot specimens as an aid in screening newborns for CAH.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
You successfully added item(s) to your cart
Congenital adrenal hyperplasia (CAH) is a genetic disorder and the most severe form of the disease can lead to a life threatening condition during the first weeks of life. The disease is caused by enzyme defects in steroid biosynthesis, the most frequent types being 21- and 11a-hydroxylase deficiency. These types represent 95% of CAH cases and in both, the 17a-OH progesterone (17OHP), a precursor of cortisol, is increased. The determination of 17OHP is thus a useful screening method for 95% of all CAH cases.
GSP Neonatal 17a-OH-progesterone assay:
The GSP Neonatal 17a-OH-progesterone assay is based on the competitive binding of europium-labeled 17OHP and 17OHP in the sample to 17OHP-specific antibodies. The fluorescence signal is inversely proportional to the analyte concentration in the sample.
All PerkinElmer neonatal products may not be available in all countries.
Disclaimer: US only
|Disorders||Congenital Adrenal Hyperplasia (CAH)|
|Product Brand Name||GSP®|
|Quantity in a Package Amount||1152.0 Units|
|Unit Size||1 Kit|
|Resource Type||File Name||File Format|
|Support Page||Newborn screening website||Link|